Determining the breadth of the respiratory syncytial virus-specific T cell response

Journal of Virology

Volumn 88, Issue 6, 2014, Pages 3135-3143

  McDermott, Daniel S ^a   Knudson, Cory J ^a   Varga, Steven M ^a,b  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; GAMMA INTERFERON; GLYCOPROTEIN; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; NUCLEOPROTEIN; PHOSPHOPROTEIN; PROTEIN;

AMINO ACID SEQUENCE; AMINO TERMINAL SEQUENCE; ANIMAL CELL; ANTIGEN DETECTION; ARTICLE; CARBOXY TERMINAL SEQUENCE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL SPECIFICITY; CELL STIMULATION; CELLULAR IMMUNITY; COMPARATIVE STUDY; CONTROLLED STUDY; EPITOPE MAPPING; FEMALE; HISTOCOMPATIBILITY COMPLEX; IMMUNOGENICITY; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; IN VITRO STUDY; MOUSE; NONHUMAN; PEPTIDE LIBRARY; PREDICTION; PRIORITY JOURNAL; PROTEIN SYNTHESIS; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RESPIRATORY SYNCYTIAL VIRUS INFECTION; T LYMPHOCYTE ACTIVATION; VIRAL CLEARANCE; VIRUS CELL INTERACTION; VIRUS GENOME;

AMINO ACID SEQUENCE; ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; EPITOPES, T-LYMPHOCYTE; FEMALE; HUMANS; INTERFERON-GAMMA; MICE; MICE, INBRED BALB C; MOLECULAR SEQUENCE DATA; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUSES; VIRAL PROTEINS;

EID: 84894517793     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.02139-13     Document Type: Article

References (63)

1. Heilman CA for NIAID and WHO. 1990.Respiratory syncytial and parainfluenza viruses. J. Infect. Dis. 161:402-406. http://dx.doi.org/10.1093/infdis/161.3.402.
2. Glezen WP, Taber LH, Frank AL, Kasel JA. 1986. Risk of primary infection and reinfection with respiratory syncytial virus. Am. J. Dis. Child. 140:543-546.
3. Hall CB, Geiman JM, Biggar R, Kotok DI, Hogan PM, Douglas GR, Jr. 1976. Respiratory syncytial virus infections within families. N. Engl. J. Med. 294:414-419. http://dx.doi.org/10.1056/NEJM197602192940803.
4. Legg JP, Hussain IR, Warner JA, Johnston SL, Warner JO. 2003. Type 1 and type 2 cytokine imbalance in acute respiratory syncytial virus bronchiolitis. Am. J. Respir. Crit. Care Med. 168:633-639. http://dx.doi.org/10.1164/rccm.200210-1148OC.
5. Shay DK, Holman RC, Newman RD, Liu LL, Stout JW, Anderson LJ. 1999. Bronchiolitis-associated hospitalizations among US children, 1980-1996. JAMA 282:1440-1446. http://dx.doi.org/10.1001/jama.282.15.1440.
6. Nair H, Nokes DJ, Gessner BD, Dherani M, Madhi SA, Singleton RJ, O'Brien KL, Roca A, Wright PF, Bruce N, Chandran A, Theodoratou E, Sutanto A, Sedyaningsih ER, Ngama M, Munywoki PK, Kartasasmita C, Simoes EA, Rudan I, Weber MW, Campbell H. 2010. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet 375:1545-1555. http://dx.doi.org/10.1016/S0140-6736(10)60206-1.
7. Falsey AR, Hennessey PA, Formica MA, Cox C, Walsh EE. 2005. Respiratory syncytial virus infection in elderly and high-risk adults. N. Engl. J. Med. 352:1749-1759. http://dx.doi.org/10.1056/NEJMoa043951.
8. Graham BS, Bunton LA, Wright PF, Karzon DT. 1991. Role of T lymphocyte subsets in the pathogenesis of primary infection and rechallenge with respiratory syncytial virus in mice. J. Clin. Invest. 88:1026-1033. http://dx.doi.org/10.1172/JCI115362.
9. Collins PL, Graham BS. 2008. Viral and host factors in human respiratory syncytial virus pathogenesis. J. Virol. 82:2040-2055. http://dx.doi.org/10.1128/JVI.01625-07.
10. Walsh EE, Peterson DR, Kalkanoglu AE, Lee FE, Falsey AR. 2013. Viral shedding and immune responses to respiratory syncytial virus infection in older adults. J. Infect. Dis. 207:1424-1432. http://dx.doi.org/10.1093/infdis/jit038.
11. Johnson JE, Gonzales RA, Olson SJ, Wright PF, Graham BS. 2007. The histopathology of fatal untreated human respiratory syncytial virus infection. Mod. Pathol. 20:108-119. http://dx.doi.org/10.1038/modpathol.3800725.
12. King JC, Jr, Burke AR, Clemens JD, Nair P, Farley JJ, Vink PE, Batlas SR, Rao M, Johnson JP. 1993. Respiratory syncytial virus illnesses in human immunodeficiency virus-and noninfected children. Pediatr. Infect. Dis. J. 12:733-739. http://dx.doi.org/10.1097/00006454-199309000-00006.
13. Castilow EM, Olson MR, Meyerholz DK, Varga SM. 2008. Differential role of gamma interferon in inhibiting pulmonary eosinophilia and exacerbating systemic disease in fusion protein-immunized mice undergoing challenge infection with respiratory syncytial virus. J. Virol. 82:2196-2207. http://dx.doi.org/10.1128/JVI.01949-07.
14. Durbin JE, Johnson TR, Durbin RK, Mertz SE, Morotti RA, Peebles RS, Graham BS. 2002. The role of IFN in respiratory syncytial virus pathogenesis. J. Immunol. 168:2944-2952.
15. Srikiatkhachorn A, Chang W, Braciale TJ. 1999. Induction of Th-1 and Th-2 responses by respiratory syncytial virus attachment glycoprotein is epitope and major histocompatibility complex independent. J. Virol. 73: 6590-6597.
16. Varga SM, Wissinger EL, Braciale TJ. 2000. The attachment (G) glycoprotein of respiratory syncytial virus contains a single immunodominant epitope that elicits both Th1 and Th2 CD4+ T cell responses. J. Immunol. 165:6487-6495.
17. McDermott DS, Varga SM. 2011. Quantifying antigen-specific CD4 T cells during a viral infection: CD4 T cell responses are larger than we think. J. Immunol. 187:5568-5576. http://dx.doi.org/10.4049/jimmunol.1102104.
18. + T cells, while that induced by Vac-F or Vac-G recombinants is mediated by antibodies. J. Virol. 66:1277-1281.
19. + cytotoxic T cells. J. Virol. 67:4086-4092.
20. Openshaw PJ, Anderson K, Wertz GW, Askonas BA. 1990. The 22,000-kilodalton protein of respiratory syncytial virus is a major target for Kdrestricted cytotoxic T lymphocytes from mice primed by infection. J. Virol. 64:1683-1689.
21. + T-lymphocyte immunodominance in respiratory syncytial virus infection. J. Virol. 81:2349-2358. http://dx.doi.org/10.1128/JVI.01910-06.
22. + T cells during experimental virus infection. J. Immunol. 167:4254-4260.
23. Johnstone C, de Leon P, Medina F, Melero JA, Garcia-Barreno B, Del Val M. 2004. Shifting immunodominance pattern of two cytotoxic Tlymphocyte epitopes in the F glycoprotein of the Long strain of respiratory syncytial virus. J. Gen. Virol. 85:3229-3238. http://dx.doi.org/10.1099/vir.0.80219-0.
24. + CD4 regulatory T cells limit pulmonary immunopathology by modulating the CD8 T cell response during respiratory syncytial virus infection. J. Immunol. 185: 2382-2392. http://dx.doi.org/10.4049/jimmunol.1000423.
25. + T cell subsets produce immunomodulatory IL-10 during respiratory syncytial virus infection. J. Immunol. 187:3145-3154. http://dx.doi.org/10.4049/jimmunol.1100764.
26. Olson MR, Hartwig SM, Varga SM. 2008. The number of respiratory syncytial virus (RSV)-specific memory CD8 T cells in the lung is critical for their ability to inhibit RSV vaccine-enhanced pulmonary eosinophilia. J. Immunol. 181:7958-7968.
27. Fulton RB, Olson MR, Varga SM. 2008. Regulation of cytokine production by virus-specific CD8 T cells in the lungs. J. Virol. 82:7799-7811. http://dx.doi.org/10.1128/JVI.00840-08.
28. Kim YPJ, Zhu Z, Tamang D, Wang P, Greenbaum J, Lundegaard C, Sette A, Lund O, Bourne PE, Nielsen M, Peters B. 2012. Immune epitope database analysis resource. Nucleic Acids Res. 40(Web Server issue): W525-W530. http://dx.doi.org/10.1093/nar/gks438.
29. Nielsen M, Lundegaard C, Worning P, Lauemoller SL, Lamberth K, Buus S, Brunak S, Lund O. 2003. Reliable prediction of T-cell epitopes using neural networks with novel sequence representations. Protein Sci. 12:1007-1017. http://dx.doi.org/10.1110/ps.0239403.
30. Lundegaard C, Lamberth K, Harndahl M, Buus S, Lund O, Nielsen M. 2008. NetMHC-3.0: accurate web accessible predictions of human, mouse and monkey MHC class I affinities for peptides of length 8-11. Nucleic Acids Res. 36:W509-W512. http://dx.doi.org/10.1093/nar/gkn202.
31. Peters B, Sette A. 2005. Generating quantitative models describing the sequence specificity of biological processes with the stabilized matrix method. BMC Bioinformatics 6:132. http://dx.doi.org/10.1186/1471-2105-6-132.
32. Sidney J, Assarsson E, Moore C, Ngo S, Pinilla C, Sette A, Peters B. 2008. Quantitative peptide binding motifs for 19 human and mouseMHC class I molecules derived using positional scanning combinatorial peptide libraries. Immunome Res. 4:2. http://dx.doi.org/10.1186/1745-7580-4-2.
33. Barends M, de Rond LG, Dormans J, van Oosten M, Boelen A, Neijens HJ, Osterhaus AD, Kimman TG. 2004. Respiratory syncytial virus, pneumonia virus of mice, and influenza A virus differently affect respiratory allergy in mice. Clin. Exp. Allergy 34:488-496. http://dx.doi.org/10.1111/j.1365-2222.2004.01906.x.
34. Dakhama A, Park JW, Taube C, Joetham A, Balhorn A, Miyahara N, Takeda K, Gelfand EW. 2005. The enhancement or prevention of airway hyperresponsiveness during reinfection with respiratory syncytial virus is critically dependent on the age at first infection and IL-13 production. J. Immunol. 175:1876-1883.
35. Mukherjee S, Lindell DM, Berlin AA, Morris SB, Shanley TP, Hershenson MB, Lukacs NW. 2011. IL-17-induced pulmonary pathogenesis during respiratory viral infection and exacerbation of allergic disease. Am. J. Pathol. 179:248-258. http://dx.doi.org/10.1016/j.ajpath.2011.03.003.
36. Newcomb DC, Boswell MG, Reiss S, Zhou W, Goleniewska K, Toki S, Harintho MT, Lukacs NW, Kolls JK, Peebles RS, Jr. 2013. IL-17A inhibits airway reactivity induced by respiratory syncytial virus infection during allergic airway inflammation. Thorax 68:717-723. http://dx.doi.org/10.1136/thoraxjnl-2012-202404.
37. Pemberton RM, Cannon MJ, Openshaw PJ, Ball LA, Wertz GW, Askonas BA. 1987. Cytotoxic T cell specificity for respiratory syncytial virus proteins: fusion protein is an important target antigen. J. Gen. Virol. 68(Part 8):2177-2182. http://dx.doi.org/10.1099/0022-1317-68-8-2177.
38. Openshaw PJ, Clarke SL, Record FM. 1992. Pulmonary eosinophilic response to respiratory syncytial virus infection in mice sensitized to the major surface glycoprotein G. Int. Immunol. 4:493-500. http://dx.doi.org/10.1093/intimm/4.4.493.
39. Bangham CR, Openshaw PJ, Ball LA, King AM, Wertz GW, Askonas BA. 1986. Human and murine cytotoxic T cells specific to respiratory syncytial virus recognize the viral nucleoprotein (N), but not the major glycoprotein (G), expressed by vaccinia virus recombinants. J. Immunol. 137:3973-3977.
40. Schmidt NW, Podyminogin RL, Butler NS, Badovinac VP, Tucker BJ, Bahjat KS, Lauer P, Reyes-Sandoval A, Hutchings CL, Moore AC, Gilbert SC, Hill AV, Bartholomay LC, Harty JT. 2008. Memory CD8 T cell responses exceeding a large but definable threshold provide long-term immunity to malaria. Proc. Natl. Acad. Sci. U.S.A. 105:14017-14022. http://dx.doi.org/10.1073/pnas.0805452105.
41. Rudensky A, Preston-Hurlburt P, Hong SC, Barlow A, Janeway CA, Jr. 1991. Sequence analysis of peptides bound to MHC class II molecules. Nature 353:622-627. http://dx.doi.org/10.1038/353622a0.
42. Hunt DF, Michel H, Dickinson TA, Shabanowitz J, Cox AL, Sakaguchi K, Appella E, Grey HM, Sette A. 1992. Peptides presented to the immune system by the murine class II major histocompatibility complex molecule I-Ad. Science 256:1817-1820. http://dx.doi.org/10.1126/science.1319610.
43. Chicz RM, Urban RG, Lane WS, Gorga JC, Stern LJ, Vignali DA, Strominger JL. 1992. Predominant naturally processed peptides bound to HLA-DR1 are derived from MHC-related molecules and are heterogeneous in size. Nature 358:764-768. http://dx.doi.org/10.1038/358764a0.
44. Chicz RM, Urban RG, Gorga JC, Vignali DA, Lane WS, Strominger JL. 1993. Specificity and promiscuity among naturally processed peptides bound to HLA-DR alleles. J. Exp. Med. 178:27-47. http://dx.doi.org/10.1084/jem.178.1.27.
45. Brown JH, Jardetzky TS, Gorga JC, Stern LJ, Urban RG, Strominger JL, Wiley DC. 1993. Three-dimensional structure of the human class II histocompatibility antigen HLA-DR1. Nature 364:33-39. http://dx.doi.org/10.1038/364033a0.
46. Fremont DH, Hendrickson WA, Marrack P, Kappler J. 1996. Structures of an MHC class II molecule with covalently bound single peptides. Science 272:1001-1004. http://dx.doi.org/10.1126/science.272.5264.1001.
47. Carson RT, Vignali KM, Woodland DL, Vignali DA. 1997. T cell receptor recognition ofMHCclass II-bound peptide flanking residues enhances immunogenicity and results in altered TCR V region usage. Immunity 7:387-399. http://dx.doi.org/10.1016/S1074-7613(00)80360-X.
48. Sant'Angelo DB, Robinson E, Janeway CA, Jr, Denzin LK. 2002. Recognition of core and flankingamino acids of MHC class II-bound peptides by theTcell receptor. Eur. J. Immunol. 32:2510-2520. http://dx.doi.org/10.1002/1521-4141 (200209)32:9<2510::AID-IMMU2510>3.0.CO;2-Q.
49. Nelson CA, Petzold SJ, Unanue ER. 1993. Identification of two distinct properties of class II major histocompatibility complex-associated peptides. Proc. Natl. Acad. Sci. U.S.A. 90:1227-1231. http://dx.doi.org/10.1073/pnas.90.4.1227.
50. + T cells that are dependent on MHC class II-bound peptide-flanking residues. J. Immunol. 169:739-749.
51. Srinivasan M, Domanico SZ, Kaumaya PT, Pierce SK. 1993. Peptides of 23 residues or greater are required to stimulate a high affinity class IIrestricted T cell response. Eur. J. Immunol. 23:1011-1016. http://dx.doi.org/10.1002/eji.1830230504.
52. Roman E, Harris DP, Jurcevic S, Ivanyi J, Moreno C. 1995. H-2-associated effects of flanking residues on the recognition of a permissive mycobacterial T-cell epitope. Immunology 86:183-189.
53. O'Brien C, Flower DR, Feighery C. 2008. Peptide length significantly influences in vitro affinity for MHC class II molecules. Immunome Res. 4:6. http://dx.doi.org/10.1186/1745-7580-4-6.
54. Wang P, Sidney J, Dow C, Mothe B, Sette A, Peters B. 2008. A systematic assessment of MHC class II peptide binding predictions and evaluation of a consensus approach. PLoS Comput. Biol. 4:e1000048. http://dx.doi.org/10.1371/journal.pcbi.1000048.
55. Wang P, Sidney J, Kim Y, Sette A, Lund O, Nielsen M, Peters B. 2010. Peptide binding predictions for HLA DR, DP and DQ molecules. BMC Bioinformatics 11:568. http://dx.doi.org/10.1186/1471-2105-11-568.
56. Collins PL, Melero JA. 2011. Progress in understanding and controlling respiratory syncytial virus: still crazy after all these years. Virus Res. 162: 80-99. http://dx.doi.org/10.1016/j.virusres.2011.09.020.
57. Lotz MT, Peebles RS, Jr. 2012. Mechanisms of respiratory syncytial virus modulation of airway immune responses. Curr. Allergy Asthma Rep. 12: 380-387. http://dx.doi.org/10.1007/s11882-012-0278-z.
58. + T cell responses directed against a broad range of epitopes. J. Immunol. 179:1058-1067.
59. + T cell responses. J. Immunol. 178:6814-6820.
60. Harrington LE, van der Most R, Whitton JL, Ahmed R. 2002. Recombinant vaccinia virus-induced T-cell immunity: quantitation of the response to the virus vector and the foreign epitope. J. Virol. 76:3329-3337. http://dx.doi.org/10.1128/JVI.76.7.3329-3337.2002.
61. + T-cell responses. J. Virol. 82:11734-11741. http://dx.doi.org/10.1128/JVI.00435-08.
62. Olson MR, Varga SM. 2007. CD8 T cells inhibit respiratory syncytial virus (RSV) vaccine-enhanced disease. J. Immunol. 179:5415-5424.
63. + T lymphocytes downregulate T helper cell type 2 cytokine secretion and pulmonary eosinophilia during experimental murine respiratory syncytial virus infection. J. Exp. Med. 186:421-432. http://dx.doi.org/10.1084/jem.186.3.421.